Page 3 - தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Celyad Oncology to Host Virtual Research & Development Webinar on July 20th Celyad Oncology SAJuly 13, 2021 GMT MONT-SAINT-GUIBERT, Belgium, July 13, 2021 (GLOBE NEWSWIRE) Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it will host a Research & Development webinar on Tuesday, July 20th at 11:30 a.m. EDT. Members of the Celyad Oncology leadership team will provide an overview of the recent advances in the R&D pipeline including insights into new preclinical allogeneic CAR T assets using shRNA technology and updates on key clinical programs. Updates will include information around the shRNA-based allogeneic candidate CYAD-211 for relapsed/refractory multiple myeloma and the industry-leading allogeneic candidate CYAD-101 for met

Mont saint guibertWaals gewestNew yorkUnited statesWalloon regionSara zelkovicExchange commissionCommunications investor relationsLifesci advisorsResearch developmentCelyad oncologyPrivate securities litigation reform actAnnual reportMedia contactsSci advisorsபுதியது யார்க்